LARGER VIALS = LARGER SAVINGS PER mg

Ipamorelin

Ipamorelin

$44.00
$44.00
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out

science Lab-Tested 99% Purity

local_shipping Fast, Discreet Shipping

school For Research Use Only

 
add_shopping_cart

-

Ordered

local_shipping

- - -

Order Ready

redeem

- - -

Delivered

Ipamorelin

Ipamorelin

$44.00
$44.00
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out

Ipamorelin is a selective ghrelin receptor (GHSR-1a) agonist that stimulates the release of growth hormone from the anterior pituitary. Unlike earlier growth hormone–releasing peptides, it shows minimal effect on cortisol and prolactin levels, making it a more targeted candidate for growth hormone modulation.

View full details
  • DESCRIPTION
  • STORAGE
  • REFERENCES

Ipamorelin is a synthetic pentapeptide and selective growth hormone secretagogue (GHS). It acts as a ghrelin receptor (GHS-R1a) agonist, stimulating the release of growth hormone (GH) from the anterior pituitary. Unlike earlier GHS compounds (such as GHRP-6 or hexarelin), Ipamorelin exhibits high selectivity for GH release with minimal effects on cortisol, ACTH, or prolactin, making it one of the most targeted GH secretagogues studied to date.

Structure

  • Type: Synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂)
  • Molecular Weight: ~711 Da
  • Mechanism: Binds ghrelin receptor (GHS-R1a) → stimulates GH secretion via hypothalamic and pituitary pathways
  • Selectivity: Minimal stimulation of ACTH, prolactin, or cortisol secretion

Research

Growth Hormone Release

  • Potently stimulates GH release in a dose-dependent manner, both in animals and humans.
  • GH release remains physiological and pulsatile, rather than continuous, reducing the risk of desensitization.

Muscle & Bone Health

  • GH stimulation leads to elevated IGF-1 levels, which support muscle protein synthesis, connective tissue repair, and bone density.
  • Studied in relation to sarcopenia, muscle wasting, and rehabilitation research.

Recovery & Anti-Aging

  • Promotes tissue healing by enhancing GH/IGF-1 pathways.
  • Investigated in regenerative medicine, metabolic health, and age-related GH decline.

Metabolic Effects

  • Improves lipid metabolism and body composition by promoting fat utilization while preserving lean mass.
  • No significant effect on appetite, unlike ghrelin.

Safety Profile

  • Favorable compared to earlier GHS analogues, with minimal off-target endocrine activity.
  • Reported side effects are generally mild and include temporary injection site reactions.

Summary

Ipamorelin is a highly selective GH secretagogue that mimics ghrelin activity without significantly affecting cortisol or prolactin. Research highlights include:

  • Strong GH release with physiological pulsatility
  • Support for muscle growth, fat metabolism, and bone health
  • Potential benefits in anti-aging, recovery, and rehabilitation research
  • Favorable safety profile compared to other GHS peptides

This peptide is supplied as a lyophilized powder. Store vials at 2–8 °C, protected from light and moisture. For long-term storage, keep unopened vials at −20 °C. After reconstitution, prepare solutions under sterile conditions, refrigerate at 2–8 °C, and use promptly. Avoid repeated freeze–thaw cycles.

1. Raun K, et al. Ipamorelin, the first selective GH secretagogue: properties and endocrine effects. *Eur J Endocrinol*. 1998;139(5):552–561. doi:10.1530/eje.0.1390552

2. Raun K, et al. Endocrine profile of the novel GH secretagogue Ipamorelin. *Eur J Endocrinol*. 2001;145(1):1–9. doi:10.1530/eje.0.1450001

3. Svensson J, et al. Ipamorelin stimulates GH release in humans without affecting ACTH or cortisol. *J Clin Endocrinol Metab*. 2000;85(2):547–553. doi:10.1210/jcem.85.2.6349

4. Bowers CY. Unnatural growth hormone-releasing peptide (GHRP) analogues. *Endocrine*. 1998;8(1):9–17. doi:10.1385/ENDO:8:1:9

5. Svensson J, et al. Comparative effects of GHRP-6, hexarelin, and Ipamorelin in humans. *J Clin Endocrinol Metab*. 1997;82(2):566–570. doi:10.1210/jcem.82.2.3748

6. Jacks T, et al. The novel GH secretagogue Ipamorelin in aged rats: GH, IGF-1, and body composition. *Growth Horm IGF Res*. 1999;9(2):93–99. doi:10.1054/ghir.1999.0101

7. Højby Rasmussen M, et al. Selectivity of Ipamorelin for GH release: absence of prolactin and cortisol stimulation. *J Endocrinol Invest*. 2002;25(8):646–652. doi:10.1007/BF03344056

8. Smith RG, et al. Peptidomimetic GH secretagogues: rationale and clinical applications. *Endocr Rev*. 1997;18(5):621–645. doi:10.1210/edrv.18.5.0317

9. Ghigo E, et al. Endocrine and metabolic effects of GH secretagogues. *Ann Endocrinol (Paris)*. 1998;59(5):389–396. PMID: 10096412

10. Svensson J, et al. Long-term administration of Ipamorelin increases GH and IGF-1 without desensitization. *Horm Metab Res*. 2002;34(2):82–86. doi:10.1055/s-2002-19873